GH Latest Press Releases

-- June 11, 2026 --

Guardant Health Announces FDA Approval of Guardant360 CDx as Companion Diagnostic for Boehringer Ingelheim's HERNEXEOS Business Wire 8:05 AM

-- May 28, 2026 --

Guardant Health and Collaborators to Present 38 Abstracts Highlighting Breadth and Expanded Clinical Utility of Guardant Liquid Biopsy Tests Powered by InfinityAI at 2026 ASCO Annual Meeting Business Wire 8:05 AM

-- May 27, 2026 --

American Cancer Society Recommends Guardant Health's Shield Blood Test in Updated Colorectal Cancer Screening Guidelines Business Wire 7:48 AM

-- May 20, 2026 --

FDA Approves New Guardant360 Liquid CDx, the Largest FDA-Approved Liquid Biopsy Panel with a 100x Expanded Footprint Business Wire 8:05 AM

-- May 18, 2026 --

Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire 4:51 PM

-- May 7, 2026 --

Guardant Health Reports First Quarter 2026 Financial Results and Increases 2026 Revenue Guidance Business Wire 4:05 PM

-- May 4, 2026 --

Guardant Health Receives FDA Approval for Guardant360 CDx as a Companion Diagnostic for Arvinas and Pfizer's VEPPANU (vepdegestrant) for Patients with ER+/HER2- Advanced Breast Cancer with ESR1 Mutations Business Wire 8:05 AM

-- April 30, 2026 --

Guardant Health Announces Multi-Year Strategic Collaboration with Nuvalent to Develop Companion Diagnostics and Support Potential Commercialization of Targeted Cancer Therapies Using the Guardant Infinity Platform Business Wire 8:05 AM

-- April 29, 2026 --

Guardant Health to Participate in Upcoming Investor Conferences Business Wire 4:05 PM

-- April 16, 2026 --

Guardant Health to Report First Quarter 2026 Financial Results on May 7, 2026 Business Wire 4:05 PM

-- March 30, 2026 --

Guardant Health's InfinityAI Real-World Evidence Supports Approval of ENHERTU for Previously Treated Patients with HER2-Positive Metastatic Solid Tumors in Japan Business Wire 8:05 AM

-- March 24, 2026 --

Verana Health and Guardant Health Partner to Advance Precision Medicine with Real-World Data PRNewswire 9:15 AM

-- March 18, 2026 --

Guardant Health to Present 28 Abstracts Highlighting Advances in Tumor Typing, Therapy Selection and Expanded Utility of Multiomic Tissue and Liquid Biopsy Testing at AACR 2026 Business Wire 8:05 AM

-- March 16, 2026 --

Guardant Health Launches Shield Multi-Cancer Detection (MCD) Test in Multiple Markets in Asia with Manulife Partnership Business Wire 8:05 AM

-- March 13, 2026 --

New Guardant Health/Harris Poll Survey Shows 92% of All Eligible Americans Believe Colorectal Cancer Blood Tests Should be Accessible and Covered Similar to Medicare Business Wire 8:05 AM

-- March 10, 2026 --

Guardant Health's Shield Blood-based Screening Test for Colorectal Cancer Now Accessible Through National Test Ordering and Collection Network of Quest Diagnostics Business Wire 8:05 AM

-- March 4, 2026 --

Guardant Health Launches Coast-to-Coast Screening Tour, Bringing Shield Colon Cancer Blood Test to Over 100 Communities Across America Business Wire 7:00 AM

-- March 3, 2026 --

Actor and Cancer Advocate Patrick Dempsey Partners with Guardant Health to Raise Awareness about Colorectal Cancer Screening and Shield Blood Test, Sharing His Experience Getting Screened Business Wire 7:00 AM

-- February 27, 2026 --

Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire 4:05 PM

-- February 19, 2026 --

Guardant Health Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Outlook Business Wire 4:05 PM

-- February 12, 2026 --

Guardant Health Launches Community Colorectal Cancer Screening Grant Program in Recognition of CRC Awareness Month, Applications Now Open PRNewswire 2:35 PM

-- February 10, 2026 --

AI, Genomics, and CRISPR Signal a New Phase of Biological Innovation Globe Newswire 9:29 AM

-- February 3, 2026 --

Guardant Health to Participate in Upcoming Investor Conferences Business Wire 4:05 PM

-- February 2, 2026 --

Largest Published Study of Molecular Residual Disease (MRD) in Stage III Colon Cancer Shows Guardant Reveal Blood Test More Precisely Identifies Risk of Recurrence After Surgery to Support Timely Treatment Decisions Business Wire 8:05 AM

-- January 29, 2026 --

Guardant Health to Report Fourth Quarter and Full Year 2025 Financial Results on February 19, 2026 Business Wire 4:05 PM

-- January 22, 2026 --

Guardant Health Receives FDA Approval for Guardant360 CDx as Companion Diagnostic for BRAFTOVI (encorafenib) Combination in Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer Business Wire 8:05 AM